

**Freedom of Information Request: 0501 2019/20**

Please detail the number of Oncology<sup>1</sup> patients treated<sup>2</sup> by your Trust with the stated therapies, during the time period January 2019 to June 2019 inclusive.

	Total Number of Patients Treated:					
	Total Number of Patients Treated	Head & Neck Cancer	Adjuvant Melanoma	Metastatic Melanoma	Non-Small Cell Lung Cancer (NSCLC)	Renal Cell Carcinoma (RCC)
Atezolizumab (Tecentriq)	10				10	
Axitinib (Inlyta)	0					
Cabozantinib (Cabometyx)	11			1		10
Cetuximab (Erbix)	1	1				
Dabrafenib (Tafinlar)	4		1	2		1
Everolimus (Afinitor)	0					
Ipilimumab (Yervoy)	2			2		
Lenvatinib (Lenvima)	0					
Nivolumab (Opdivo)	17	2	1	2	2	10
Pazopanib (Votrient)	19					19

Pembrolizumab (Keytruda)	45				44	1
Sorafenib (Nexavar)	0					
Sunitinib (Sutent)	9					9
Tivozanib (Fotivda)	0					
Vemurafenib (Zelboraf)	0					